KalVista's oral HAE treatment Ekterly receives EU and Swiss approval
PositiveFinancial Markets

KalVista's oral treatment for hereditary angioedema, Ekterly, has received approval from both the EU and Switzerland, marking a significant milestone in the management of this rare condition. This approval not only highlights the efficacy of Ekterly but also provides patients with a new option for treatment, potentially improving their quality of life. The significance of this development lies in its promise to address unmet medical needs in the HAE community.
— Curated by the World Pulse Now AI Editorial System